News about Regulation

CDSCO lists 1,700 BIS standards to strengthen medical device compliance and hospital planning

CDSCO lists 1,700 BIS standards to strengthen medical device compliance and hospital planning

The Central Drugs Standard Control Organisation (CDSCO) has released a comprehensive list of around 1,700 standards developed under the Medical Equipment and Hospital Planning Division (MHD) of the Bureau of Indian Standards (BIS).

Regulation | 28/10/2025 | By Darshana 211

FDA Approves Genentech's Gazyva for Treatment of Lupus Nephritis

FDA Approves Genentech's Gazyva for Treatment of Lupus Nephritis

The US Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab), developed by Genentech, for the treatment of adults with lupus nephritis (LN), also known as lupus-related kidney disease.

Regulation | 21/10/2025 | By Dineshwori 106

Alembic Pharmaceuticals Gets USFDA Nod for Triamcinolone Acetonide Injection

Alembic Pharmaceuticals Gets USFDA Nod for Triamcinolone Acetonide Injection

The approved ANDA, Triamcinolone Acetonide Injection, is therapeutically equivalent to the Reference Listed Drug (RLD) product, Kenalog-40 Injectable Suspension, of Bristol-Myers Squibb company.

Regulation | 21/10/2025 | By Dineshwori 149

FDA Expands Indications for Celltrion's YUFLYMA to Include Pediatric and Adolescent Patients

FDA Expands Indications for Celltrion's YUFLYMA to Include Pediatric and Adolescent Patients

Celltrion has announced that the US Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA (adalimumab-aaty) and its unbranded version to include the treatment of hidradenitis suppurativa (HS) in adolescent patients aged 12 years and older, and uveitis (UV) in pediatric patients aged 2 years and older.

Regulation | 17/10/2025 | By Dineshwori 264

After India, Innocan Pharma Secures Patent Allowance in Japan for Liposomal CBD Delivery Platform

After India, Innocan Pharma Secures Patent Allowance in Japan for Liposomal CBD Delivery Platform

Israel-based pharmaceutical technology company Innocan Pharma Corporation has announced that its patent for the liposomal delivery platform LPT-CBD has been allowed in Japan and will be officially granted following the completion of administrative process.

Regulation | 16/10/2025 | By Dineshwori 147

Marksans Pharma's UK subsidiary Relonchem Secures MHRA Approval for Clonidine Tablets

Marksans Pharma's UK subsidiary Relonchem Secures MHRA Approval for Clonidine Tablets

Marksans Pharma’s wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets.

Regulation | 15/10/2025 | By Dineshwori 176

Celltrion Receives US FDA Approval for EYLEA Biosimilar EYDENZELT

Celltrion Receives US FDA Approval for EYLEA Biosimilar EYDENZELT

Celltrion has received approval from the US Food and Drug Administration (FDA) for EYDENZELT (aflibercept-boav), a biosimilar to EYLEA (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).

Regulation | 11/10/2025 | By Dineshwori 214

WHO Prequalifies Shanchol Oral Cholera Vaccine

WHO Prequalifies Shanchol Oral Cholera Vaccine

Shanchol remains the only oral cholera vaccine manufactured in India with WHO prequalification, underscoring India’s critical role in ensuring continuity of global supply.

Regulation | 07/10/2025 | By Dineshwori 274

Biocon and Carnegie Secure Tentative FDA Approval for Rifaximin Tablets

Biocon and Carnegie Secure Tentative FDA Approval for Rifaximin Tablets

Biocon Pharma, a wholly owned subsidiary of Biocon Ltd., in partnership with Carnegie Pharmaceuticals, has received tentative approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg.

Regulation | 07/10/2025 | By Dineshwori 207

Zydus Receives USFDA Approval for Deflazacort Oral Suspension

Zydus Receives USFDA Approval for Deflazacort Oral Suspension

Zydus stated that deflazacort oral suspension will be produced at Doppel, Italy.

Regulation | 06/10/2025 | By Dineshwori 120

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members